HEMICLOR (chlorthalidone) by R-Pharm US is long-acting oral diuretic with antihypertensive activity. First approved in 2025.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
HEMICLOR (chlorthalidone) is a long-acting oral thiazide-like diuretic approved in March 2025 for hypertension management. It works by inhibiting sodium and chloride reabsorption in the ascending limb of Henle's loop, leading to increased sodium and water excretion that reduces blood volume and cardiac output. The drug's antihypertensive effect stems from sustained diuresis and electrolyte depletion.
Recently approved product in growth phase signals strong market expansion opportunity with expanding commercial team investment from R-Pharm US.
long-acting oral diuretic with antihypertensive activity. Chlorthalidone produces diuresis with increased excretion of sodium and chloride. The site of action appears to be the cortical diluting segment of the ascending limb of Henle's loop of the nephron. The diuretic effects of chlorthalidone…
Thiazide-like Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Worked on HEMICLOR at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on HEMICLOR offers exposure to launch-phase commercialization of an established drug class with clear market entry strategy. Career growth depends on rapid market penetration execution and managing competitive pressure in a commoditized therapeutic area.